U.S. Pharma Stock News

AMETEK (NYSE:AME) announced a $5 billion acquisition of Indicor Instrumentation, expanding its reach in industrial and scientific instrumentation. The deal is described by the company as transformative for its mission critical instrumentation portfolio and recurring revenue exposure. This transaction is one of the largest in AMETEK’s history and is expected to reshape its long term revenue mix and operating profile. For investors tracking NYSE:AME, this announcement comes with the stock at...

In early May 2026, Flowserve Corporation completed a US$500 million offering of 5.70% senior unsecured notes due 2036, primarily to fund its planned acquisition of Trillium Flow Technologies’ Valves Division and for general corporate purposes, alongside reporting first-quarter sales of US$1,068.27 million and net income of US$81.68 million. At the same time, the company lowered its 2026 total sales growth guidance to a range of 3% to 6%, signaling a more cautious outlook even as it pursues...

Ares Management Corporation has already reported first-quarter 2026 results, with revenue rising to US$1,396.44 million and net income to US$142.59 million, while also lifting its quarterly common dividend to US$1.35 per share and maintaining preferred dividends. The appointment of Peter Ogilvie as Chief Operating Officer and Head of Strategy, alongside record fundraising and expanding assets under management, highlights Ares’ focus on scaling its global alternatives platform and reinforcing...

Q1 2026 earnings as the starting point Mettler-Toledo International (MTD) has just reported Q1 2026 sales of US$947.13 million and net income of US$169.45 million, with earnings per share from continuing operations slightly higher than a year earlier. See our latest analysis for Mettler-Toledo International. The latest Q1 report comes after a period where the stock has shown mixed momentum, with a 3.9% 30 day share price return but a 6.5% decline year to date, while the 1 year total...

Entegris, Inc. recently reported first-quarter 2026 results showing higher sales and net income year on year, issued stronger earnings guidance for the next two quarters, amended its revolving credit facility to US$750.00 million through 2031, and appointed industry veteran Sukhi Nagesh as CFO effective May 18, 2026. Together, these updates highlight Entegris’ focus on reinforcing its balance sheet, tightening operations, and deepening semiconductor-sector expertise in its finance leadership...

Clover Health Investments (CLOV) opened Q1 2026 with revenue of US$749.2 million and basic EPS of US$0.05, alongside net income excluding extra items of US$27.3 million, giving investors a clean read on the core business. Over the last five reported quarters, revenue has moved from US$336.9 million in Q4 2024 to US$749.2 million in Q1 2026, while quarterly basic EPS has shifted from a loss of US$0.04 to a profit of US$0.05. This sets up this update as a key check on whether those improving...

Reynolds Consumer Products Inc. ( NASDAQ:REYN ) defied analyst predictions to release its quarterly results, which were...

If you are wondering whether Vertex Pharmaceuticals at around US$425 per share offers good value or is already pricing in too much optimism, this article breaks down what the current stock price may be implying. The stock is around US$425 after a 0.6% slip over the last week, a 1.6% decline over the last month and a 6.0% decline year to date. The 1 year return sits at 1.1%, the 3 year at 21.3% and the 5 year at 98.3%. Recent attention around Vertex has focused on its product pipeline and...

Cencora (COR) has put up a busy Q2 2026, with revenue of about US$78.4b, basic EPS of US$8.44 and net income of US$1,641.3m setting the tone for this earnings season update. Over the past six reported quarters, revenue has moved between roughly US$75.5b and US$86.0b while quarterly EPS has ranged from a loss of US$1.75 to a high of US$8.44. This gives investors a clear view of how the earnings line has tracked alongside a very large top line. Taken together with trailing twelve month EPS of...

Shareholders will be ecstatic, with their stake up 21% over the past week following uniQure N.V. 's ( NASDAQ:QURE...

The investors in JELD-WEN Holding, Inc. 's ( NYSE:JELD ) will be rubbing their hands together with glee today, after...

It's been a pretty great week for IQVIA Holdings Inc. ( NYSE:IQV ) shareholders, with its shares surging 13% to US$179...

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) last week reported its latest first-quarter results, which makes it a...

Marathon Petroleum Corporation ( NYSE:MPC ) just released its first-quarter report and things are looking bullish...

CVS Health Corporation ( NYSE:CVS ) defied analyst predictions to release its quarterly results, which were ahead of...

It's been a good week for BorgWarner Inc. ( NYSE:BWA ) shareholders, because the company has just released its latest...

There's been a notable change in appetite for Tigo Energy, Inc. ( NASDAQ:TYGO ) shares in the week since its...

Acushnet Holdings Corp. reported first-quarter 2026 results, with sales rising to US$752.98 million while net income and earnings per share declined versus a year earlier. Over the same period, the company completed a multi-year buyback program totaling 19,275,829 shares for about US$1.02 billion, materially shrinking its share count. With revenue growth supported by new Titleist product launches but profits under pressure, we’ll examine how this shapes Acushnet’s investment narrative. The...

Gold.com (GOLD) just posted Q3 2026 results with revenue of about US$10.4b and net income of US$59.5m, equal to EPS of US$2.17, against a backdrop of 112.2% earnings growth over the past year and low net margins of around 0.3%. The company has seen quarterly revenue move from US$3.0b in Q3 2025 to US$10.4b in Q3 2026, while EPS shifted from a loss of US$0.36 to a profit of US$2.17 over the same periods, highlighting a combination of earnings momentum and thin margins for investors. See our...

We wouldn't blame The Vita Coco Company, Inc. ( NASDAQ:COCO ) shareholders if they were a little worried about the fact...

If you are wondering whether Viridian Therapeutics at around US$16.97 is priced for opportunity or risk, the key question is what that tag really says about the business. The stock has recently shown sharp moves, with returns of 25.9% over 7 days and 21.6% over 30 days, while year to date it is down 44.7% and up 32.8% over the past year. This mix of recent gains and earlier weakness has put valuation back in focus as investors reassess what they are willing to pay for Viridian Therapeutics...

LCI Industries and Patrick Industries have ended merger of equals talks, halting plans to combine their RV supply operations. The termination marks a key corporate event that could affect how both businesses position themselves in the recreational vehicle supply sector. Investors now have to assess NYSE:LCII on a standalone basis, without potential merger related changes to scale or product breadth. LCI Industries, ticker NYSE:LCII, recently closed at $116.43, with the stock showing a 41.7%...

If you are wondering whether Globalstar's recent share price action still leaves any value on the table, it can help to start with a clear view of what the current valuation actually reflects so you can set expectations. The stock closed at US$81.48, with a 1% decline over the last 7 days, a 10.3% gain over 30 days, a 27.3% gain year to date, a 303.6% return over 1 year, a 432.5% return over 3 years, and a 412.5% return over 5 years. This performance already sets a high bar for what the...

Dutch Bros (BROS) opened Q1 2026 with revenue of US$464.4 million and basic EPS of US$0.13, alongside trailing 12 month revenue of US$1.7b and EPS of US$0.63 that frame the latest quarter within a larger earnings upswing in the data. Over recent periods, revenue has moved from US$355.2 million in Q1 2025 to US$464.4 million in Q1 2026, while quarterly EPS has ranged between US$0.13 and US$0.20, setting up a story where higher sales and advancing earnings feed into improving margins and a...